The 20th Awaji International Forum on Infection and Immunity
Sep 7 - Sep 9, 2022Hybrid
The 20th Awaji International Forum on Infection and Immunity
Sep 7 - Sep 9, 2022Hybrid
[P-13]Development of a highly safe and effective live attenuated SARS-CoV-2 vaccine based on temperature sensitivity-associated mutations
○Shinya Okamura1,2, Akiho Yoshida1,2, Shiro Takekawa1, Hirotaka Ebina1,2,3(1.The Research Foundation for Microbial Disease of Osaka University, Suita, Osaka, Japan, 2.Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan, 3.6Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan)
Password required to view
Abstract password authentication.
You need a password to log in to the dedicated site for participants where you can browse abstracts, view e-posters and deliver an online presentation with Zoom meeting.
The forum secretariat will send the password to those who completed the registration on Monday, August 29 (tentative) via email.
You need a password to log in to the dedicated site for participants where you can browse abstracts, view e-posters and deliver an online presentation with Zoom meeting.
The forum secretariat will send the password to those who completed the registration on Monday, August 29 (tentative) via email.